Investment Rating - The report maintains a "Recommended" rating for the new materials industry [1] Core Insights - The new materials sector is positioned as a crucial direction for the chemical industry, currently experiencing rapid growth in downstream demand. With policy support and technological breakthroughs, domestic new materials are expected to accelerate into a long-term growth phase. The report emphasizes that "one generation of materials leads to one generation of industry," highlighting the foundational nature of the new materials industry as the material basis for other sectors [3][4]. Summary by Sections 1. Electronic Information Sector - Focus areas include semiconductor materials, display materials, and 5G materials. Samsung Display has officially launched mass production of the 8.6 generation OLED panels, which will be used in new laptops this year [5][20]. 2. Aerospace Sector - Key materials of interest are PI films, precision ceramics, and carbon fibers. The successful suborbital flight test of the Lihong No. 1 vehicle demonstrates advancements in low-cost and flexible launch capabilities [7]. 3. New Energy Sector - Focus on photovoltaic materials, lithium-ion batteries, proton exchange membranes, and hydrogen storage materials. India is projected to become the second-largest solar market globally by 2026, driven by steady installation growth [9]. 4. Biotechnology Sector - Key areas include synthetic biology and scientific services. A team from Tsinghua University in Shenzhen has developed a 3D-printed "mini heart" that mimics the rhythmic beating of a real heart, with future applications in organ printing anticipated [11]. 5. Energy Conservation and Environmental Protection Sector - Focus on adsorbent resins, membrane materials, and biodegradable plastics. The Ministry of Industry and Information Technology has launched an action plan to promote high-quality development of industrial internet platforms, aiming for over 450 influential platforms by 2028 [13]. 6. Key Companies and Earnings Forecast - The report highlights several companies with their respective stock prices and earnings per share (EPS) forecasts for 2024A, 2025E, and 2026E, along with their price-to-earnings (PE) ratios and investment ratings. Notable companies include: - Ruihua Tai (688323.SH): EPS forecast of 0.26 for 2026E, rated as "Increase" [14] - Guangwei Composite (300699.SZ): EPS forecast of 0.97 for 2026E, rated as "Buy" [14] - Zhongfu Shenying (688295.SH): EPS forecast of 0.23 for 2026E, rated as "Buy" [14] - Wanrun Co., Ltd. (002643.SZ): EPS forecast of 0.53 for 2026E, rated as "Buy" [14] - Dinglong Co., Ltd. (300054.SZ): EPS forecast of 0.96 for 2026E, rated as "Buy" [14]

Core Insights - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative sector, which is seen as a new growth point that can drive industrial structure optimization and economic model transformation [1]. Group 1: Current State and Trends - The "2025 China Synthetic Biomanufacturing Industry Development White Paper" was officially released on August 1, highlighting the current state and trends of biomanufacturing [1]. - The report analyzes the global biomanufacturing industry, including key platform facilities and a comparative study of the US and China in this field [5]. Group 2: Policy Landscape - The white paper discusses major policies affecting biomanufacturing both domestically and internationally for the years 2024-2025 [5]. Group 3: Industry Map and Applications - It provides a comprehensive map of the Chinese biomanufacturing industry and analyzes the industry chain along with key application directions, including biomanufacturing in pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [5]. Group 4: Key Enterprises - The report identifies ten leading enterprises in the Chinese biomanufacturing sector, showcasing their significance in the industry [5][6]. Group 5: Company Strategies - It outlines the synthetic biology layout directions of 15 listed companies and summarizes their development strategies [5][6]. Group 6: Investment and Challenges - The white paper reviews the investment and financing situation in domestic synthetic biology from 2024 to mid-2025 and discusses the challenges faced by the biomanufacturing industry in China, along with proposed countermeasures [5][6].

Investment and Capacity Expansion - In 2025, China's nylon industry is set for explosive growth with planned production capacity exceeding 8 million tons and total investment reaching 170 billion yuan, driven by breakthroughs in adiponitrile technology [1] - Multiple nylon 66 projects are in the planning stages, including projects from Henan, Shanxi, Fujian, and Sichuan, which will expand domestic nylon 66 capacity and promote industry integration [1] Project Launches and Developments - The establishment of the Anhui Kaysai Times Biobased Battery Shell Manufacturing Base, with an investment of 500 million yuan, aims to produce 2.5 million biobased nylon 56 battery shells annually [2] - Yongrong's 60,000 tons/year nylon fiber project in Vietnam is part of its global strategy to supply the Southeast Asian textile market [3] - China Pingmei Shenma Group has initiated a 200,000 tons/year project to enhance its nylon 66 raw material supply [4] - Zhejiang Petrochemical's 500,000 tons/year nylon 66 project is progressing, utilizing advanced technology for production [5] - Yangzi Petrochemical's 3.04 billion yuan project for long-chain nylon is under environmental review [6] - New South Mountain Chemical's 110,000 tons/year high-end nylon project has received approval [7] - Fujian Koten's 90,000 tons/year high-temperature nylon resin project is in the environmental review stage [8] - Zhuhai Wantong's 40,000 tons/year biobased high-temperature nylon project is also under environmental review [9] - Pingdingshan Shenma's 1,000 tons/year high-temperature nylon 6T resin project is in the approval stage [10] - Xuyang's 200,000 tons/year nylon 66 project has been accepted for environmental review [11] - Kaysai's 900,000 tons/year biobased polyamide project is continuing construction [12] - Huafeng Group's 3,000 tons/year special nylon digital workshop project has been approved [13] - Hubei Aoshen's 30,000 tons/year special nylon project is in the environmental review stage [14] - New Hope's 10 billion yuan new materials industry chain project has commenced [15] - Shanghai Jieda's special nylon project has signed a cooperation agreement [16] - Huitong's high-temperature nylon and PEEK polymer project has settled in Shanghai [17] - Henan Shenma's 12,000 tons/year recycled nylon project has been signed [18] - Yulong Petrochemical's 400,000 tons/year nylon 66 project is under construction [19] Product Innovations - Wanhua Chemical has launched a new nylon 12 elastomer to enhance textile belt performance [20] - Invista has achieved a breakthrough in nylon 6,6 recycling technology, allowing for 100% post-consumer recycled content [22] - DOMO Chemicals showcased its TECHNYL® MAX series, offering metal replacement solutions with high performance [23] - Kingfa Technology has made significant progress in biobased nylon, with a focus on low-carbon, halogen-free flame-retardant materials [24] - Shengtong Polygen has developed high-temperature nylon production technology [25] - Shenda's ultra-high-strength nylon 66 industrial yarn has passed mid-term acceptance [26] - Yipin Biological has introduced a plant-based nylon product, "Yilun®," for various textile applications [27] - New Silk Road has achieved full-process localization technology for special nylon 66 long filaments [28] - Yingpu Sanwei has released two new nylon materials for 3D printing applications [29] - BASF has launched several new sustainable nylon products, including a commercialized recycled polyamide 6 production facility [30] - Evonik has expanded applications for long-chain polyamides in various industries [31] - Kaysai Biotech is collaborating with CATL to develop biobased nylon battery shells [33] - Huitong has showcased new high-temperature nylon materials for automotive applications [34] - Sinopec Hunan Petrochemical has completed small-scale research on high-temperature nylon technologies [35] - Asahi Kasei is set to launch a new PA66 material with significant performance improvements [36]

Core Viewpoint - Kaisa Bio (688065.SH) is currently trading at 57.62 yuan, reflecting a decline of 3.60% and is in a state of breaking its initial public offering price [1] Group 1: Company Overview - Kaisa Bio was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 12, 2020, with a total public offering of 41,668,198 shares, accounting for 10.00% of the total shares post-issuance, at an issuance price of 133.45 yuan per share [1] - On its first trading day, Kaisa Bio reached a peak price of 198 yuan, marking the highest price since its listing [2] - The total funds raised by Kaisa Bio amounted to 556.06 million yuan, with a net amount of 528.00 million yuan, exceeding the original plan by 58.11 million yuan [2] Group 2: Fund Utilization - The funds raised were intended for several projects, including a 40,000 tons/year bio-based dodecanedioic acid project, a bio-based polyamide engineering research center, and a 30,000 tons/year long-chain dicarboxylic acid project, as well as for working capital [2] - Kaisa Bio's total fundraising from two rounds amounts to 11.487 billion yuan [4] Group 3: Shareholder Information - The actual controllers of Kaisa Bio are Xiucai Liu, Xiaowen Ma, and Charlie Chi Liu, who are American citizens of Chinese descent [2] - On March 28, 2025, Kaisa Bio disclosed a report on the issuance of A-shares to specific entities, with the controlling shareholder Shanghai Yaoxiu being a company controlled by Xiucai Liu's family [3] - The issuance involved 137,911,755 shares at a price of 42.97 yuan per share, raising a total of approximately 5.93 billion yuan, which is intended for working capital and loan repayment [3]

Market Overview - The chemical products sector experienced a decline of 0.55% on January 14, with Chenghe Technology leading the losses [1] - The Shanghai Composite Index closed at 4126.09, down 0.31%, while the Shenzhen Component Index rose to 14248.6, up 0.56% [1] Top Gainers in Chemical Sector - Qicai Chemical (300758) saw a significant increase of 20.01%, closing at 16.85 with a trading volume of 524,100 shares and a turnover of 832 million [1] - Changhua Chemical (301518) rose by 12.77%, closing at 44.60 with a trading volume of 124,200 shares and a turnover of 519 million [1] - Demei Chemical (002054) increased by 9.99%, closing at 8.81 with a trading volume of 420,300 shares and a turnover of 360 million [1] Top Losers in Chemical Sector - Chenghe Technology (688625) declined by 5.79%, closing at 58.71 with a trading volume of 88,500 shares and a turnover of 525 million [2] - Duofuduo (002407) fell by 4.31%, closing at 31.55 with a trading volume of 1,265,100 shares and a turnover of 404.6 million [2] - Kaisa Bio (688065) decreased by 3.97%, closing at 59.77 with a trading volume of 158,000 shares and a turnover of 965 million [2] Capital Flow Analysis - The chemical products sector experienced a net outflow of 1.757 billion from institutional investors, while retail investors saw a net inflow of 1.333 billion [2] - The top stocks with significant net inflows from retail investors include Qicai Chemical (300758) with a net inflow of 256 million [3] - Demei Chemical (002054) also had a notable net inflow of 108 million from retail investors [3]

由药融圈&Synbio深波联合发起，药融圈产业研究院精心编纂的 《2025中国合成生物制造产业发 展白皮书》 （以下简称《研究报告》），已于8月1日 在Synbio China 第三届中国合成生物学"科 学家+企业家+投资家"博览会正式发布！ 本白皮书介绍了生物制造的发展现状及趋势，分析了生物制造的产业链和重点应用方向， 并精选 出中国生物制造产业10大链主企业，整理了15家上市公司合成生物学布局方向以及20大热门品种 ，同时探讨了生物制造面临的挑战，最终提出了针对性的政策建议，供业内参考 。 领取方式： 关注本公众号，扫码添加下方微信获取 添加请备注：单位+职位+姓名 封面一览 Synthetic Biology 深波 1 251 息息与人脉精准链接平台 2025中国合成生物 制造产业发展白皮书 近年来，生物制造的热度居高不下，作为新兴的战略性领域，生物制造因其创新性和对传 统生产方式的颠覆性，被视为新的增长点，有助于推动产业结构优化和经济模式的转变。 China's synthetic biomanufacturing industry Development White Paper 目录 一、 凯赛生物 ...

Core Viewpoint - Biomanufacturing is identified as a key future industry in China's 14th Five-Year Plan, expected to create a market worth trillions in the next decade, driven by advancements in technology and policy support [2][5]. Group 1: Industry Overview - The biomanufacturing industry in China is nearing a total scale of 1 trillion yuan, with fermentation capacity accounting for over 70% of the global total [2][4]. - Shenzhen has become a hub for biomanufacturing, with 40% of newly established companies in this sector located there in the past three years, showcasing a significant industry clustering effect [4]. - The industry is supported by a comprehensive system of policy, funding, and technological advancements as outlined in the 14th Five-Year Plan [5]. Group 2: Key Enterprises - The article identifies 100 core enterprises in biomanufacturing, spanning the entire industry chain from upstream technology development to downstream commercial applications [7]. - Notable companies include: - Huada Technology, a leader in gene sequencing technology [17]. - Kaisa Biotech, which has achieved over 80% market share in the global long-chain dicarboxylic acid market [21]. - WuXi Biologics, representing China's capabilities in the global biopharmaceutical industry [27]. Group 3: Upstream Innovations - The upstream sector focuses on providing essential tools and technologies for research and production, with a shift towards domestic innovation and smart integration [16]. - Key trends include the localization of critical tools and the rise of AI-driven platform companies that enhance research efficiency [16][17]. - Over 75% of the 20 identified upstream enterprises are private, indicating a vibrant innovation landscape [16]. Group 4: Midstream Developments - The midstream sector is characterized by a dual structure of "upgraders" and "disruptors," with companies like Meihua Biotech and Chuaning Biotech leading in traditional fermentation while others like Kaisa Biotech innovate with new bioproducts [20][21]. - This segment contains the highest number of enterprises, with 40 out of the 100 identified companies, emphasizing the importance of production capacity and cost control [20]. Group 5: Downstream Applications - The downstream sector serves as a critical market for biomanufacturing, focusing on medical, consumer, and agricultural applications [25]. - Companies like Muyuan Foods exemplify the cost-saving potential of biomanufacturing in agriculture, while WuXi Biologics and Kelaiying represent the pharmaceutical sector's output capabilities [26][27]. - Future trends indicate a broadening of applications into new areas such as biobased textiles and environmental remediation [27].

Group 1 - The core viewpoint of the article highlights the positive outlook for the petrochemical industry, with a focus on the ongoing capital inflow into the petrochemical ETF and the anticipated market trends for 2026 [1] - The petrochemical ETF (159731) has seen a net inflow of 57.72 million yuan over the past four days, indicating strong buying interest [1] - CITIC Securities expresses optimism for the cross-year market, emphasizing the importance of focusing on future industry hotspots, AI, and the rising prices of resource products [1] Group 2 - The petrochemical industry is currently at the bottom of its cycle, with expectations for improvement in supply-demand dynamics and profitability due to supply-side structural reforms [1] - The basic chemical industry accounts for 59.2% and the oil and petrochemical industry for 32.6% of the Shenwan primary industry distribution, indicating a significant concentration in these sectors [1] - The article suggests that technology and resource products will be the two core investment themes for A-shares this year, with frequent sector rotation and style switching anticipated [1]

Market Overview - The chemical products sector experienced a decline of 0.29% on January 13, with Qiaoyuan Co. leading the drop [1] - The Shanghai Composite Index closed at 4138.76, down 0.64%, while the Shenzhen Component Index closed at 14169.4, down 1.37% [1] Top Performers - Huaheng Biological (688639) saw a significant increase of 13.79%, closing at 41.34 with a trading volume of 419,600 shares and a transaction value of 1.721 billion [1] - Chenghe Technology (688625) rose by 12.29%, closing at 62.32 with a trading volume of 109,000 shares and a transaction value of 672 million [1] - Kaisa Biological (688065) increased by 12.14%, closing at 62.24 with a trading volume of 177,800 shares [1] Underperformers - Qiaoyuan Co. (301286) fell by 8.67%, closing at 47.41 with a trading volume of 53,000 shares and a transaction value of 258 million [2] - Hangqing Co. (002430) decreased by 6.99%, closing at 32.06 with a trading volume of 311,600 shares [2] - Taihe Technology (300801) dropped by 6.72%, closing at 30.39 with a trading volume of 173,200 shares [2] Capital Flow - The chemical products sector saw a net outflow of 642 million from institutional investors and 357 million from retail investors, while retail investors had a net inflow of 999 million [2] - The capital flow data indicates a mixed sentiment among different investor types within the sector [2] Individual Stock Capital Flow - Duoliangduo (002407) had a net inflow of 224 million from institutional investors, while it experienced a net outflow of 1.09 billion from retail investors [3] - Wanhu Chemical (600309) saw a net inflow of 189 million from institutional investors, with a net outflow of 76.596 million from retail investors [3] - Yahua Group (002497) had a net inflow of 154 million from institutional investors, while retail investors experienced a net outflow of 17.488 million [3]

Investment Rating - The industry investment rating is "Overweight" [3] Core Insights - The chemical industry is expected to continue its differentiated trend in 2026, with recommendations to focus on synthetic biology, pesticides, chromatography media, sweeteners, vitamins, light hydrocarbon chemicals, COC polymers, and MDI [6][7] - The arrival of a pivotal moment in synthetic biology is anticipated, driven by the adjustment of energy structures, which may disrupt fossil-based materials and favor low-energy products [7] - The implementation of quota policies for third-generation refrigerants is expected to lead to a high prosperity cycle, with demand remaining stable due to market expansion in Southeast Asia [8] - The electronic specialty gases market is characterized by high technical barriers and value, presenting significant opportunities for domestic substitution [10] - The trend of light hydrocarbon chemicals is becoming global, with a shift towards lighter raw materials in the olefin industry, which is expected to lead to a revaluation of leading companies in this sector [10] - The industrialization process of COC polymers is accelerating, with domestic companies likely to break through supply bottlenecks and expand market space [11] - Potash fertilizer prices are expected to rebound as the industry enters a destocking cycle, with supply pressures easing due to production cuts by major companies [12] - The MDI market is characterized by oligopoly, with a favorable supply structure expected to develop as demand gradually recovers [13] Industry Performance - The chemical sector's overall performance ranked 12th with a weekly change of 5.03%, outperforming the Shanghai Composite Index by 1.21 percentage points [5][22] - The top three performing sub-sectors were inorganic salts (10.92%), modified plastics (9.94%), and oil and gas refining engineering (8.67%) [25] Company Performance - The top three performing companies in the chemical sector for the week were Pulit (42.59%), Dawi Technology (35.34%), and Sanfu Co., Ltd. (32.29%) [29][30] - The companies with the largest declines included Hangzhou High-tech (-11.24%), Yahua Group (-6.59%), and Wind God Co., Ltd. (-5.48%) [31][32] Industry Dynamics - A recent anti-dumping investigation has been initiated against imports of dichlorodihydrosilane from Japan, which is expected to impact the domestic industry [38] - The restructuring of Sinopec and China Aviation Oil is a significant event in the state-owned enterprise reform landscape, aiming to enhance competitiveness in a complex international environment [38]